Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)
Conditions: Mycosis Fungoides Interventions: Drug: Mogamulizumab-Kpkc; Device: Phototherapy Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Kyowa Hakko Kirin Pharma, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials

Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis
Conditions: Lymphomatoid Papulosis; Mycosis Fungoides Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides Interventions: Drug: Hypericin; Drug: Mechlorethamine Topical Gel Sponsors: Soligenix Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 28, 2023 Category: Research Source Type: clinical trials

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma: a Multicenter Observational Study
Conditions: Cutaneous T Cell Lymphoma; Cutaneous T-Cell Lymphoma/Mycosis Fungoides; Cutaneous T-Cell Lymphoma/Sezary Syndrome Sponsors: Fondazione Italiana Linfomi - ETS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
Conditions: Cutaneous T Cell Lymphoma; Cutaneous T-Cell Lymphoma/Mycosis Fungoides; Cutaneous T-Cell Lymphoma/Sezary Syndrome Sponsors: Fondazione Italiana Linfomi - ETS Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials

Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
KT-333 Phase 1 oncology trial ongoing with an update including initial evaluation of its clinical antitumor activity in patients expected in the fourth quarter of 2023 Fast Track designation can potentially accelerate KT-333’s development... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - September 18, 2023 Category: Pharmaceuticals Source Type: clinical trials

Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study
Condition:   Cutaneous T-cell Lymphoma Intervention:   Drug: Linperlisib in combined with Chidamide Sponsor:   Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2023 Category: Research Source Type: clinical trials